Investigational Drug Information for Vadimezan
✉ Email this page to a colleague
What is the development status for investigational drug Vadimezan?
Vadimezan is an investigational drug.
There have been 4 clinical trials for Vadimezan.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2010.
The most common disease conditions in clinical trials are Neoplasms, Small Cell Lung Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, University of Glasgow, and Swiss Group for Clinical Cancer Research.
Summary for Vadimezan
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,680 |
| WIPO Patent Applications | 906 |
| Japanese Patent Applications | 326 |
| Clinical Trial Progress | Phase 2 (2010-01-01) |
| Vendors | 117 |
Recent Clinical Trials for Vadimezan
| Title | Sponsor | Phase |
|---|---|---|
| Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung Cancer | Swiss Group for Clinical Cancer Research | Phase 2 |
| Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 Inhibitor | Novartis Pharmaceuticals | Phase 1 |
| Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 |
Clinical Trial Summary for Vadimezan
Top disease conditions for Vadimezan
Top clinical trial sponsors for Vadimezan
US Patents for Vadimezan
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
